Literature DB >> 7509016

Acute myeloblastic leukemia (AML-M2) expressing CD19 B-cell lymphoid antigen without myeloid surface antigens.

S H Khalil, J M Jackson, M H Qari, H Pyle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7509016     DOI： 10.1016/0145-2126(94)90131-7

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndrome.

Authors:  Kazuya Tsuboi; Makoto Yazaki; Hiroshi Miwa; Shinsuke Iida; Shogo Banno; Atsushi Wakita; Masakazu Nitta; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

Review 2.  Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Authors:  Michael M Boyiadzis; Madhav V Dhodapkar; Renier J Brentjens; James N Kochenderfer; Sattva S Neelapu; Marcela V Maus; David L Porter; David G Maloney; Stephan A Grupp; Crystal L Mackall; Carl H June; Michael R Bishop
Journal:  J Immunother Cancer       Date:  2018-12-04       Impact factor: 13.751

3.  CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

Authors:  Kemeng Wang; Guoqing Wei; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2012-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.